NCT05755737View on ClinicalTrials.gov

A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Vasovagal Syncope (VVS)Syncope
Interventions
DRUG

Ondansetron

Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)

DRUG

Placebo

Matching placebo identical in appearance.

Trial Locations (1)

T2N 4Z6

RECRUITING

University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER